Challenges of Staging Lung Cancer with the New TNM Classification (9th edition)

Brierley JD, Gospodarowicz MK, Wittekind C, editors. TNM Classification of Malignant Tumours. 8th ed. London: Wiley-Blackwell; 2017.

Goldstraw P, Chansky K, Crowley J, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (8th) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11:39-51. doi:10.1016/j.jtho.2015.09.009.

Asamura H, Chansky K, Crowley J, Goldstraw P, Rami-Porta R, Groome P, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10:1675-84. doi:10.1097/JTO.0000000000000078.

Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017;15:193-203. doi:10.1016/j.chest.2016.10.010.

Silvestri GA, Gonzalez AV, Jantz MA, Lichtenstein SE, Gould MK, Garcia DA, et al. Methods for Staging Non-Small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013;143:e2115-e2505. doi:10.1379/chest.12-2355.

Provencio M, Nadal E, Insa A, García-Campelo MR, Casal Rubio J, Dómine M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADiM): an open-label, multicentre, single-arm, phase 2 trial. Ann Oncol. 2021;32:747-54. doi:10.1016/s1470-2045(20)30453-8.

WuYL,TsuboiM,HeJ,John T,Grohe C, Majem M,et al.Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383:171-23. doi:10.1056/NEDMoa2027071.

Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010i): a randomized, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344-57. doi:10.1016/S0140-6736(21)02098-5.

Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256-65. doi:10.1093/jnci/djs629.

Crombag LM, Dooms C, Stigt JA, Tournoy KG, Schuurbiers OC, Ninaber MK, et al. Systematic and combined endosonographic staging of lung cancer (SCORE study). Eur Respir J. 2019;53:1800800. doi: 10.1183/13993003.00800-2018.

Vilmann P, Clementsen PF, Colella S, Siemsen M, De Leyn P, Dumonceau JM, et al. Combined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer. European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Eur Respir J. 2015;46:40-60. doi: 10.1183/09031936.00064515.

von Bartheld MB, Rabe KF, Annema JT. Transaortic EUS-guided FNA in the diagnosis of lung tumors and lymph nodes. Gastrointest Endosc. 2009;69:345-9. doi: 10.1016/j.gie.2008.06.021.

Leiro-Fernández V, Fernández-Villar A. Mediastinal staging for non-small cell lung cancer. Transl Lung Cancer Res. 2021;10:496-505. doi: 10.21037/lcr.2020.03.08.

Gwon HR, La Woo A, Yong SH, Park Y, Kim SY, Kim EY, et al. Factors affecting accuracy of clinical staging in resectable non-small cell lung cancer in a real-world study. Thorac Cancer. 2024;15:730-7. doi: 10.1111/1759-7714.15253.

Tirapu Puyal JM, Múgica Atorrasagasti N, Leal Arranz MV, Santana Astudillo JC, Lopez Duque JC, Ortega Cornunian L, et al. Cytologic Contamination of the Sampling Needle in Endobronchial Ultrasound. Arch Bronconetumol. 2022;58:367-8. doi:10.1016/j.arbres.2021.07.01.

Rei J, Castro P, Guerra M, Miranda J. Outcomes Of Surgically Treated N2-Positive Non-Small Cell Lung Cancer. Port J Card Thorac Vasc Surg. 2024;302:3-9. doi:10.48729/pjctvs.320.

Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19:1007-27. doi:10.1016/j.jtho.2024.02.01.

Lee JM. Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non-small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testing. J Thorac Cardiovasc Surg. 2024;168:1281-8.

van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:442-50. doi:10.1093/jnci/djk093.

Sorensen CV, Ganz PA, Cole SW, Pedersen LA, Sorensen HT, Cronin-Fenton DP, et al. Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol. 2013;31:2265-72. doi:10.1200/JCO.2012.43.9190.

Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379-86. doi:10.1016/S0140-6736(09)60737-6.

Eberhardt WE, Pöttgen C, Cauler TC, Friedel G, Veit S, Heinrich V, et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015;33:4194-201. doi:10.1200/JCO.2015.62.6812.

Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021;16:860-7. doi:10.1016/j.jtho.2020.12.015.

Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MC, et al. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024;12(e009677. doi:10.1136/jitc-2024-009677.

Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al. Alecithib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024;390:1265-76. doi:10.1056/NEJMoa2310532.

De Leyn P, Dooms C, Kuzdzai J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45:787-98. doi:10.1093/ejcts/exu028.

DuComb EA, Tonelli BA, Tuo Y, Cole BF, Mori V, Bates JH, et al. Evidence for Expanding Invasive Mediastinal Staging for Peripheral Tl Lung Tumors. Chest. 2020;158:2192-9. doi:10.1016/j.chest.2020.05.607.

Bousema JE, Dijkgraaf MG, van der Heijden EH, Verhagen AF, Annema JT, et al. Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial. J Clin Oncol. 2023;41:3805-15. doi:10.1200/JCO.22.01728.